Archive · 2026 · October 2026

Daily digest — 2026-10-05

2026-10-05

Five science items today: a GSPT1 glue degrader for glioblastoma, a DNA-origami degrader of mutant KRAS mRNA, an ACER2 inhibitor, the first PAPP-A inhibitors and a click-triggered warhead. Business adds Summit's Datroway–ivonescimab collaboration and JCR's Italfarmaco license.

⚗️

Medicinal Chemistry

4 articles

2026-10-03 · ⚗️GSPT1 molecular glue degrader (CRBN) · Journal of Medicinal Chemistry (ACS)

Oral isoindolinone GSPT1 glue degrader LG-NE-29 targets glioblastoma models

A viability-based phenotypic screen flagged GSPT1 as a vulnerability in glioblastoma cells, where resistance to temozolomide arises quickly.
Optimizing an isoindolinone series for metabolic stability gave LG-NE-29, a molecular glue that drives CRBN-dependent ubiquitination and proteasomal degradation of GSPT1.
It is reported to avoid the metabolic weaknesses of earlier scaffolds, and to be orally bioavailable with activity in glioblastoma xenograft models.

💡 Points

Isoindolinone CRBN glues usually die on metabolism, so fixing that liability is the real story here. Before I believe it, I'd want the GSPT1 DC50/Dmax, proteome-wide selectivity (IKZF1/3, other neosubstrates), and oral PK with brain exposure. GSPT1 degradation is also broadly cytotoxic, so the therapeutic window in normal cells matters.

Discovery of LG-NE-29: An Orally Bioavailable GSPT1 Molecular Glue Degrader Effective in Glioblastoma Xenograft Models ↗

2026-09-30 · ⚗️PAPP-A (pappalysin metalloproteinase) active-site inhibitors, peptide-derived phosphinate/phosphonate · bioRxiv

First synthetic PAPP-A inhibitors dampen IGF-1 signaling in cells and in vivo

Peptides & macrocycles Structure-based design

PAPP-A is a secreted metalloproteinase that cleaves IGF-binding proteins to control local IGF signaling, offering an alternative to IGF-1R targeting.
Inhibitors were built on an IGFBP-5-derived anchor sequence, with the scissile bond replaced by phosphinate or phosphonate groups, giving potent and selective compounds.
Cryo-EM showed how they bind the active site, and they blocked IGFBP-4 and IGFBP-5 cleavage.
They suppressed IGF-1 signaling in A549 cells, comparably to stanniocalcin-1, and inhibited Papp-aa-dependent signaling in vivo.

💡 Points

Swapping the scissile bond of an IGFBP-5 anchor sequence for a phosphinate or phosphonate is classic transition-state mimicry, and a cryo-EM pose would validate the zinc-binding hypothesis. Going after the protease rather than IGF-1R is smart for selectivity. I'd want Ki values against related metalloproteinases, and cell permeability and stability of these peptidic leads, before trusting the in vivo claim.

Synthetic inhibitors of pregnancy-associated plasma protein-A regulate IGF-1 signaling in vitro and in vivo ↗

2026-09-29 · ⚗️ACER2 (alkaline ceramidase 2) inhibitor · bioRxiv

KPB82, a ceramide-mimetic sulfonamide, is a selective ACER2 inhibitor in a bioRxiv preprint

Safety & toxicology

ACER2 hydrolyses ceramides to sphingosine and fatty acids, and no pharmacological tool for it existed.
KPB82, a dodecane sulfonamide carrying a ceramide-like hydroxyphenylpropyl group, inhibited ACER2 potently, with minimal activity on acid and neutral ceramidases and none on ACER1 or ACER3.
Kinetics were competitive, and docking into an AlphaFold3 model placed it in the substrate pocket near the Zn2+-binding histidines.
The title reports protection of tumor and primary cells from doxorubicin cytotoxicity.

💡 Points

No ACER2 tool compound until now, so a competitive, ACER1/ACER3-sparing hit matters. A dodecane sulfonamide with a hydroxyphenylpropyl headgroup reads like a ceramide mimic, and the docked pose near the Zn2+ histidines is only an AlphaFold3 hypothesis. I'd want IC50s, an SAR series, and cellular target engagement before trusting the doxorubicin rescue.

KPB82 potently and selectively inhibits ACER2 and protects tumor and primary cells from doxorubicin-induced cytotoxicity ↗

2026-09-12 · ⚗️Bioorthogonally activated covalent warheads (masked Michael acceptors) · Journal of the American Chemical Society (ACS)J. Am. Chem. Soc. 2026, 148 (38), 41661

Cyclooctyne click triggers Cope elimination to unmask Michael acceptor warheads and release payloads

Covalent drugs

Michael acceptors are masked with a hydroxylamine; a bioorthogonal reaction with a cyclooctyne triggers Cope elimination, regenerating the electrophile under mild conditions.
The approach covers several warhead types, including unsaturated carbonyl, cyano, sulfonyl, phosphonate and maleimide, with tunable activation rates.
Functionalized cyclooctynes can release an imaging or functional payload at the same time, giving a signal that reports activation.
Applied to covalent inhibitors, it gave controlled activation in cells.

💡 Points

Could a masked warhead finally fix the off-target reactivity of acrylamide-class leads? Caging the Michael acceptor as a hydroxylamine and uncaging it by cyclooctyne click is a neat way to turn on covalency only where you dose the trigger. From the abstract alone I would want the rate constants, whether the hydroxylamine-bearing prodrug keeps target affinity, and how the cyclooctyne's size and lipophilicity compare with a conventional warhead.

A Click-Triggered Bioorthogonal Strategy for Dual Activation of Covalent Warheads and Reporter Payloads ↗

🧬

Pharmacology

1 article

2026-10-02 · 🧬DNA origami-delivered barnase RNA degrader (mutant KRAS mRNA) · ACS Pharmacology & Translational Science (ACS)

DNA origami carrying a barnase variant is built to cleave mutant KRAS mRNA

Targeted protein degradation Oligonucleotides & RNA RAS pathway

Mutant KRAS variants are structurally diverse and lack druggable pockets, which has limited small-molecule inhibitors.
The authors assemble a degrader on a six-helix-bundle DNA origami scaffold that targets the mRNA rather than the protein.
One module pairs an engineered barnase variant with a programmable recognition strand, cutting RNA directly without relying on endogenous cellular machinery; a second module is designed for cell penetration.

💡 Points

If KRAS has no pocket worth chasing, going after the mRNA is a fair dodge, and a catalytic barnase gives a clean mechanism: sequence-guided cleavage, no reliance on endogenous machinery. But I would want to see the data before getting excited. How well does the recognition strand discriminate single-base mutants from wild-type KRAS, given barnase's cleavage is catalytic and unforgiving of leakage? And does it survive delivery, with real potency in cells and a sensible comparison to siRNA or ASO?

An Integrated DNA Origami-Based RNA Degrader for Targeted Degradation of Oncogenic Mutant KRAS mRNA ↗

🏢

Industry News

2 articles

2026-10-02 · 🏢Licensing · AnswersNews · JCR Pharmaceuticals / Italfarmaco

JCR grants Italfarmaco US, EU and Latin America rights to Hunter syndrome drug JR-141

Licensing & partnerships

JCR Pharmaceuticals signed an exclusive license with Italfarmaco for JR-141 (pabinafusp alfa; Izcargo in Japan) in the US, Europe and Latin America.
The blood-brain-barrier-penetrating enzyme replacement therapy targets Hunter syndrome (MPS II); it was launched in Japan in 2021 and is in Phase 3.
Italfarmaco will commercialize after approvals; JCR keeps manufacturing and receives upfront, milestone, royalty and supply revenue. Amounts were not disclosed.

💡 Points

Undisclosed economics make this a structure story, not a price story. JCR hands Italfarmaco commercialization in the US, Europe and Latin America but keeps manufacturing and supply revenue, which preserves margin on a complex biologic. For Italfarmaco it is a rare-disease pipeline add; what I would want to see is Phase 3 data and regulatory timelines before judging value.

第一三共「ダトロウェイ」併用療法開発で米サミットと提携／JCRファーマ「イズカーゴ」欧米販売でライセンス契約など｜製薬業界きょうのニュースまとめ読み（2026年10月2日） ↗

2026-10-02 · 🏢Clinical collaboration · Endpoints News · Summit Therapeutics / AstraZeneca / Daiichi Sankyo

Summit, AstraZeneca and Daiichi Sankyo to test ivonescimab plus Datroway, starting with Phase III in 1L TNBC

Antibody–drug conjugates Oncology Licensing & partnerships

Summit, AstraZeneca and Daiichi Sankyo announced a clinical collaboration combining ivonescimab (PD-1xVEGF bispecific) with Datroway (datopotamab deruxtecan, a TROP2-directed ADC).
It starts with a Phase III study in first-line triple-negative breast cancer, with plans to expand to other settings including lung cancer.
The companies will share trial costs, and each retains development and commercial rights to its own drug.

💡 Points

Three companies, two assets, and no one gives up rights: this is a cost-sharing structure, not a licensing deal. For Summit, pairing ivonescimab with a validated TROP2 ADC borrows AstraZeneca and Daiichi's TNBC credibility and trial muscle. For the big partners, it is a cheap hedge on the PD-1xVEGF class. I would want to see the control arm and endpoints before judging how much it de-risks.

Summit partners with AstraZeneca and Daiichi; Eccogene earns $50M milestone ↗